{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:16:41Z","timestamp":1793974601790,"version":"4.8.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016420","name":"California Walnut Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016420","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clnu.2022.08.001","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T17:18:30Z","timestamp":1659979110000},"page":"2195-2206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Statins\u2019 efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0053-2440","authenticated-orcid":false,"given":"Chrysoula","family":"Boutari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis D.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8621-7478","authenticated-orcid":false,"given":"Dimitrios","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National","volume":"vol. 178","author":"Lazo","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.clnu.2022.08.001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2022.08.001_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154203","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","volume":"111","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.clnu.2022.08.001_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154781","article-title":"Addressing the epidemic of fatty liver disease: a call to action, a call to collaboration, a call to moving the field forward","volume":"122","author":"Boutari","year":"2021","journal-title":"Metab Clin Exp"},{"issue":"6","key":"10.1016\/j.clnu.2022.08.001_bib7","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.clnu.2022.08.001_bib8","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/j.1440-1746.2006.04698.x","article-title":"Significant correlations between severe fatty liver and risk factors for metabolic syndrome","volume":"22","author":"Hsiao","year":"2007","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.clnu.2022.08.001_bib9","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clnu.2022.08.001_bib10","series-title":"Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells","first-page":"275","author":"Wei","year":"2006"},{"key":"10.1016\/j.clnu.2022.08.001_bib11","doi-asserted-by":"crossref","DOI":"10.1055\/s-2001-12925","article-title":"Nonalcoholic steatohepatitis: definition and pathology","volume":"21","author":"Brunt","year":"2001","journal-title":"Semin Liver Dis"},{"issue":"5","key":"10.1016\/j.clnu.2022.08.001_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/00365520500320060","article-title":"Rosuvastatin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH)","volume":"41","author":"Ahmed","year":"2006","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.clnu.2022.08.001_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0028-1091979","article-title":"Abnormalities of lipid metabolism in nonalcoholic fatty liver disease","volume":"28","author":"Cheung","year":"2008","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.clnu.2022.08.001_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0021-9150(00)00407-X","article-title":"Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes","volume":"153","author":"Isusi","year":"2000","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.dld.2014.07.170","article-title":"The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease","volume":"47","author":"Pastori","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.clnu.2022.08.001_bib16","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Molecular sciences treatments for NAFLD: state of art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnu.2022.08.001_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2019.02.028","article-title":"Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes","volume":"284","author":"Nascimbeni","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.clnu.2022.08.001_bib19","article-title":"Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"2013","author":"Eslami","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1515\/abm-2018-0026","article-title":"Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Rattanachaisit","year":"2018","journal-title":"Asian Biomed"},{"issue":"4","key":"10.1016\/j.clnu.2022.08.001_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101816","article-title":"Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis","volume":"46","author":"Fatima","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clnu.2022.08.001_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clnu.2022.08.001_bib23","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clnu.2022.08.001_bib24","series-title":"GRADE handbook","year":"2021"},{"issue":"2","key":"10.1016\/j.clnu.2022.08.001_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I 2 Index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"issue":"25","key":"10.1016\/j.clnu.2022.08.001_bib26","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.clnu.2022.08.001_bib27","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1872-034X.2012.01034.x","article-title":"Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study","volume":"42","author":"Nakahara","year":"2012","journal-title":"Hepatol Res"},{"issue":"8","key":"10.1016\/j.clnu.2022.08.001_bib28","first-page":"OC19","article-title":"Comparative effect of insulin sensitizers and statin on metabolic profile and ultrasonographical score in non alcoholic fatty liver disease","volume":"10","author":"Rana","year":"2016","journal-title":"J\u00a0Clin Diagn Res"},{"issue":"6","key":"10.1016\/j.clnu.2022.08.001_bib29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.dld.2011.12.013","article-title":"Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-\u03b1-lowering property","volume":"44","author":"Hyogo","year":"2012","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.clnu.2022.08.001_bib30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","article-title":"Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study","volume":"22","author":"Athyros","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.clnu.2022.08.001_bib31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1155\/2003\/857869","article-title":"Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis","volume":"17","author":"Kiyici","year":"2003","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib32","first-page":"39","article-title":"Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study","volume":"16","author":"Georgescu","year":"2007","journal-title":"J\u00a0Gastrointest Liver Dis"},{"issue":"12","key":"10.1016\/j.clnu.2022.08.001_bib33","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.metabol.2008.07.030","article-title":"Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia","volume":"57","author":"Hyogo","year":"2008","journal-title":"Metab Clin Exp"},{"issue":"10","key":"10.1016\/j.clnu.2022.08.001_bib34","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A\u00a0pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"11","key":"10.1016\/j.clnu.2022.08.001_bib35","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1872-034X.2011.00849.x","article-title":"Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study","volume":"41","author":"Hyogo","year":"2011","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study","volume":"47","author":"Ekstedt","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.clnu.2022.08.001_bib37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MAJ.0b013e318213e526","article-title":"Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease","volume":"342","author":"Maroni","year":"2011","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.clnu.2022.08.001_bib38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2174\/1570161118666201015152921","article-title":"Prevalence, diagnosis, and treatment with 3 different statins of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?","volume":"19","author":"Sfikas","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"issue":"4","key":"10.1016\/j.clnu.2022.08.001_bib39","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clnu.2022.08.001_bib40","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.clnu.2022.08.001_bib41","first-page":"00385","article-title":"Development and validation of a score for fibrotic nonalcoholic steatohepatitis","volume":"S1542-3565","author":"Tavaglione","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clnu.2022.08.001_bib42","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity: focus on patients with fatty liver","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clnu.2022.08.001_bib43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-0773.1990.tb00840.x","article-title":"Biochemical changes and morphological alterations of the liver in Guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor)","volume":"67","author":"Horsmans","year":"1990","journal-title":"Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.clnu.2022.08.001_bib44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1592\/phco.24.6.584.34738","article-title":"Statins and liver toxicity: a meta-analysis","volume":"24","author":"de Denus","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.clnu.2022.08.001_bib45","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.amjmed.2006.07.033","article-title":"Impact of statin dosing intensity on transaminase and creatine kinase","volume":"120","author":"Dale","year":"2007","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.clnu.2022.08.001_bib46","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clnu.2022.08.001_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","article-title":"Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians","volume":"340","author":"Rzouq","year":"2010","journal-title":"Am J Med Sci"},{"issue":"2","key":"10.1016\/j.clnu.2022.08.001_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.numecd.2016.09.011","article-title":"Under-prescription of statins in patients with non-alcoholic fatty liver disease","volume":"27","author":"Del Ben","year":"2017","journal-title":"Nutr Metabol Cardiovasc Dis"},{"issue":"10","key":"10.1016\/j.clnu.2022.08.001_bib49","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/apt.14976","article-title":"Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany","volume":"48","author":"Labenz","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clnu.2022.08.001_bib50","first-page":"17","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk","volume":"71","author":"Athyros","year":"2017","journal-title":"An Expert Panel Statement. Metabolism"},{"issue":"14","key":"10.1016\/j.clnu.2022.08.001_bib51","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.clnu.2022.08.001_bib52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.clnu.2022.08.001_bib53","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clnu.2022.08.001_bib54","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"154770","author":"Muzurovi\u0107","year":"2021","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.clnu.2022.08.001_bib55","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clnu.2022.08.001_bib56","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2022.08.001_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154779","article-title":"The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis","volume":"120","author":"Liu","year":"2021","journal-title":"Metab Clin Exp"},{"issue":"8","key":"10.1016\/j.clnu.2022.08.001_bib58","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.metabol.2015.09.017","article-title":"Non-alcoholic fatty liver disease and risk of cardiovascular disease","volume":"65","author":"Lonardo","year":"2016","journal-title":"Metab Clin Exp"},{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib59","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"9756","key":"10.1016\/j.clnu.2022.08.001_bib60","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.clnu.2022.08.001_bib61","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","article-title":"Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels","volume":"168","author":"Tikkanen","year":"2013","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.clnu.2022.08.001_bib62","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/157016111797484080","article-title":"Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women","volume":"9","author":"Athyros","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"issue":"2","key":"10.1016\/j.clnu.2022.08.001_bib63","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clnu.2022.08.001_bib64","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"2","key":"10.1016\/j.clnu.2022.08.001_bib66","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1089-3261(03)00024-2","article-title":"Hepatotoxicity of hypolipidemic drugs","volume":"7","author":"Parra","year":"2003","journal-title":"Clin Liver Dis"},{"issue":"12","key":"10.1016\/j.clnu.2022.08.001_bib67","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.117.027067","article-title":"Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke","volume":"136","author":"Heller","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.clnu.2022.08.001_bib68","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clnu.2022.08.001_bib69","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/hep.28567","article-title":"Statins and portal hypertension: a tale of two models","volume":"63","author":"Arab","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clnu.2022.08.001_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-019-1147-1","article-title":"Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10.1016\/j.clnu.2022.08.001_bib71","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561422002874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561422002874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T01:09:35Z","timestamp":1759367375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561422002874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0261561422002874"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2022.08.001","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins\u2019 efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2022.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.","name":"copyright","label":"Copyright"}]}}